Novel animal models to dissect how lung macrophages contribute to SARS-CoV2 alveolar pathology and respiratory failure
Project Number5K01OD031968-04
Contact PI/Project LeaderGLUDISH, DAVID W
Awardee OrganizationCORNELL UNIVERSITY
Description
Abstract Text
This application seeks support for a research-emphasis veterinarian embarking on an independent career as a
translational veterinarian-scientist. The applicant proposes to study macrophages as drivers of SARS-CoV2-
induced lung damage in humans and mouse models, and will develop novel indicator mice to report SARS-CoV2
cellular targets in mice. This multi-disciplinary approach brings together leading experts in lung biology,
macrophage biology, virology, mouse genetics and pulmonary pathology. At Cornell University College of
Veterinary Medicine, the applicant will perform research in the laboratories of Drs. David Russell and Dr. Hector
Aguilar-Carreño (Department of Microbiology and Immunology), with histopathology analyses performed in the
laboratory of Dr. Gerald Duhamel (Department of Biomedical Sciences). For specific hands-on training in lung
epithelial repair assays, the applicant will work in the laboratory of Dr. Carla Kim (Harvard Medical
School/Children’s Hospital Boston). Dr. Russell, primary mentor, is an expert in macrophage biology and their
interaction with several lung pathogens, notably M.tuberculosis and HIV. He has a proven track record in training
post-doctoral veterinarian-scientists that have gone on to tenure-track positions with federal research funding.
Dr. Aguilar-Carreño has published extensively on the entry and egress of enveloped viruses with emphasis on
paramyxoviruses, and recently has adapted his well-described mouse challenge platform for antiviral and
vaccine discovery, toward SARS-CoV2. Dr. Duhamel is a veterinary anatomic pathologist with a research focus
in infectious disease, including lung pathogens in mice. Finally, Dr. Carla Kim is a pioneer in lung epithelial repair
and stem cell biology. Adding breadth and depth to the proposed work, the applicant has assembled a team of
enthusiastic collaborators (with two practicing MD physicians), including leaders in mouse genetics and lung
injury (Drs. Kahn and Morrisey), hyaluronan biology (Dr. Hascall), and human pulmonary pathology (Dr.
Borczuk). The research environment at Cornell is exceptional in the disciplines of infectious disease and
comparative pathology, while the combined expertise of Drs. Kim and Borczuk adds a strong translational and
integrative focus on drivers of alveolar damage. The proposal will probe how resident and recruited
macrophages are dysregulated during SARS-CoV2 in mice, whether dependent on direct viral infection of
macrophages or on environmental cues. In Aim 1, reporter mice will be generated to identify SARS-CoV2-
infected cells during infection and upon asymptomatic recovery. During Aim 2, the nature of macrophage subsets
as viral targets will be studied, and their resulting functional deficits determined using assays developed by Dr.
Russell. In Aim 3, viral challenge studies in human Ace2-expressing mice will interrogate macrophages as drivers
of alveolar damage, and test whether macrophage interventions improve clinical outcomes in mice. The
candidate will begin this research as Senior Research Associate in the Department of Microbiology and
Immunology (75% research effort), with an expected junior faculty transition in the independent award phase.
Public Health Relevance Statement
Project Narrative
SARS-CoV2 is an ongoing global pandemic that targets the most vulnerable members of our society with
persistent, overwhelming inflammation of the lungs that can eventually cause respiratory failure and death.
However, the specific factors that act locally in the lungs to determine disease severity remain unknown. These
studies will contribute powerful new tools to obtain clinically relevant information about macrophages, the
predominant immune cells in SARS-CoV2 infection, including whether they prevent repair of lung damage during
infection, and whether they may be potential drug targets to reduce disease severity and death in humans
infected with SARS-CoV2.
No Sub Projects information available for 5K01OD031968-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K01OD031968-04
Patents
No Patents information available for 5K01OD031968-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K01OD031968-04
Clinical Studies
No Clinical Studies information available for 5K01OD031968-04
News and More
Related News Releases
No news release information available for 5K01OD031968-04
History
No Historical information available for 5K01OD031968-04
Similar Projects
No Similar Projects information available for 5K01OD031968-04